In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations

Ibrexafungerp is a first-in-class glucan synthase inhibitor. In vitro activity was determined for 89 Candida glabrata isolates with molecularly identified FKS1 or FKS2 mutations conferring resistance to the echinocandins. All isolates were resistant to at least one echinocandin (i.e., anidulafungin,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Antimicrob Agents Chemother
Autori principali: Nunnally, Natalie S., Etienne, Kizee A., Angulo, David, Lockhart, Shawn R., Berkow, Elizabeth L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2019
Soggetti:
Susceptibility
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6811432/
https://ncbi.nlm.nih.gov/pubmed/31481447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01692-19
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi